Fate Therapeutics (FATE) said new data from FT819's phase 1 study in patients with moderate to severe systemic lupus erythematosus showed no dose-limiting toxicities in the first three patients.

The drug showed rapid, deep and sustained depletion of CD19+ B cells in the periphery and a "favorable safety profile," the company said Monday in a statement.

One patient reaching six-month follow-up achieved clinical remission and remains free of immunosuppressive therapy, the company said.

Shares of the company rose 1.5% in recent after-hours activity.

Price: 2.7598, Change: +0.04, Percent Change: +1.46